Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement

Executive Summary

• Algernon Health Inc. entered into a strategic business and investment agreement with American Molecular Imaging (AMI), granting AMI exclusive radiology reading services for all planned U.S. neuroimaging clinics.
• AMI will make a total USD $500,000 strategic investment – $250,000 in Algernon’s private placement and $250,000 in the newly created subsidiary Algernon USA LLC.
• Algernon announced a non‑dilutive equipment financing with Catalyst MedTech for four FDA‑cleared PET scanner systems (valued > CAD $4 million) and an option to acquire six additional systems for future clinics.

Key Details

• Agreement Scope: AMI receives exclusive contract to interpret PET scan radiology exams for all of Algernon’s planned U.S. brain‑specific neuroimaging clinics.
• Strategic Investment:
• USD $250,000 into Algernon’s recently announced private placement.
• USD $250,000 into Algernon USA LLC (subsidiary overseeing U.S. operations).
• Definitive documentation expected within 60 days.
• Clinic Plans: First U.S. flagship neuroimaging clinic slated for early 2026; additional clinics to follow across the United States focusing on Alzheimer’s disease and other neurological conditions.
• Equipment Financing with Catalyst MedTech:
• Four Oncovision CareMiBrain™ PET scanner systems (U.S. FDA‑cleared) secured under a non‑dilutive deal valued at > CAD $4 million.
• Option to acquire six additional systems on an adjusted cost basis for future clinic roll‑out.
• Use of Proceeds: Investment and equipment financing will fund the establishment, staffing, and operational launch of the U.S. neuroimaging network, including technology acquisition, facility build‑out, and radiology service contracts.
• Regulatory Notices: Securities subject to a four‑month hold period; not registered under U.S. securities laws – offering limited to non‑U.S. persons.

Notable Quotes

• “We are very pleased to have entered into this Agreement with AMI… we can ensure that we deliver the highest level of patient care possible while operating our clinics effectively and efficiently.” – Christopher J. Moreau, CEO, Algernon Health
• “We are truly excited to be a part of Algernon’s plan to bring this new brain optimized PET scan technology to the market…” – Jaideep S. Sohi, MD, CEO, American Molecular Imaging